

Cost-Effectiveness of Pneumococcal Vaccination¹ and U Underserved and General Population Adults Aged²<

Journal of Community Health

45, 111-120

DOI: 10.1007/s10900-019-00716-8

Citation Report

#	ARTICLE	IF	CITATIONS
2	Costâ€Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1271-1278.	1.3	7
3	A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease. <i>Journal of Public Health</i> , 2021, , .	1.0	4
4	Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? \hat{r} value of information analysis. <i>Vaccine</i> , 2021, 39, 3608-3613.	1.7	1
5	Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. <i>Vaccine</i> , 2022, 40, 2635-2646.	1.7	6
6	Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults&A65-years-old. <i>Vaccine</i> , 2022, 40, 7312-7320.	1.7	2